Dentofacial deformity is a disorder of the volume and morphological structure of the jaws and the positional relationship between the maxilla and mandible caused by abnormal development of the jaws, which is manifested by abnormal facial morphology, malocclusion and dysfunction of the stomatognathic system. Orthognathic surgery is an important means of treating dentofacial deformity, and the development of specialized nursing plans for orthognathic surgery needs to be developed based on the diagnostic and treatment characteristics and needs of different disease courses. This article proposed recommended nursing practices as a means of constructing a specialized nursing model for orthognathic surgery and providing standardized management for orthognathic patients throughout the entire cycle by reviewing previous literature and summarizing the nursing practice experience of our hospital in treating more than 3 000 patients undergoing orthognathic surgery and classify clinical nursing evidence according to the Oxford Evidence Grading Standards. The model is divided into three main phases: prehospital early referral care, in-hospital intensive care, and posthospital extended care, and contains five modules: case management, psychological intervention, nutritional guidance, management of complications, and functional recovery. In the pre-hospital early referral care stage, the specific nursing measures include digital surgical design, psychological care, and nutritional guidance; in the in-hospital cluster care stage, the specific nursing measures include four modules, such as management of complications, orofacial functional recovery, nutritional instructions, and psychological interventions; and in the post-hospital extended care stage, the patients need to be provided with case management, psychological guidance, nutritional guidance, and other nursing care. Post-hospital extended care stage, need to provide patients with case management, psychological guidance, nutritional guidance and other care.

ObjectiveTo investigate the effects and mechanism of the combination of arsenic trioxide （ATO） and its dimethylarsinic acid （DMAV） metabolite on apoptosis of human acute promyelocytic leukemia NB4 cells by affecting the balance of metabolic reaction. MethodsThe rats were injected with the same amount of sterile normal saline， ATO（1.6 mg·kg^-1）， and DMAV（4， 8， 16， and 32 mg·kg^-1） combined with ATO（1.6 mg·kg^-1）， respectively， to obtain the corresponding drug-containing serum. The effect of drug-containing serum on the proliferation of NB4 cells was detected by the cell counting kit-8 （CCK-8 ）method. Apoptosis was detected by flow cytometry with Annexin-V-FITC/PI double staining. Intracellular reactive oxygen species （ROS） accumulation was detected by flow cytometry using fluorescent probe DCFH-DA. The changes of mitochondrial membrane potential （Δψm） were detected by the fluorescence probe JC-1. Western blot detected the expression of apoptosis-related proteins， namely B-cell lymphoma-2（Bcl-2）-associated X protein（Bax）/Bcl-2， Cytochrome C， cleaved Caspase-9， and cleaved Caspase-3， as well as c-Jun N-terminal kinase（JNK） phosphorylation levels. Results①The Combination of the two drugs had a higher proliferation inhibition rate and more apoptosis than ATO alone. ②The combination of two drugs can significantly increase the production of ROS compared with any single treatment group. ③The Δψm was significantly reduced in the two-drug combination group compared with any single treatment group. ④Compared with either group， the combination group significantly released Cytochrome C， significantly down-regulated the expression of Bcl-2， and up-regulated the expression of Bax， cleaved Caspase-3， and cleaved Caspase-9. ⑤The phosphorylation level of JNK was significantly up-regulated in the two-drug combination group compared with any single treatment group. ConclusionThe combination of DMAV and ATO may synergistically induce mitochondrial apoptosis through ROS-mediated oxidative stress， triggering Δψm dissipation and Cytochrome C release. By activating Caspase-9/Caspase-3 and the phosphorylation level of JNK， the Bcl-2 family protein （Bax/Bcl-2） was regulated to promote the apoptosis of NB4 cells.

Understanding the regulatory networks for germ cell fate specification is necessary to developing strategies for improving the efficiency of germ cell production in vitro. In this study, we developed a coupled screening strategy that took advantage of an arrayed bi-molecular fluorescence complementation (BiFC) platform for protein-protein interaction screens and epiblast-like cell (EpiLC)-induction assays using reporter mouse embryonic stem cells (mESCs). Investigation of candidate interaction partners of core human pluripotent factors OCT4, NANOG, KLF4 and SOX2 in EpiLC differentiation assays identified novel primordial germ cell (PGC)-inducing factors including BEN-domain (BEND/Bend) family members. Through RNA-seq, ChIP-seq, and ATAC-seq analyses, we showed that Bend5 worked together with Bend4 and helped mark chromatin boundaries to promote EpiLC induction in vitro. Our findings suggest that BEND/Bend proteins represent a new family of transcriptional modulators and chromatin boundary factors that participate in gene expression regulation during early germline development.
Animals ; Cell Differentiation/genetics* ; Chromatin/metabolism* ; Embryonic Stem Cells ; Germ Cells/metabolism* ; Germ Layers/metabolism* ; Mice

Adenine ; Animals ; Gene Editing ; Mice ; Zygote ; metabolism